E 13RAlternative Names: E13R
Latest Information Update: 28 May 2007
At a glance
- Originator BresaGen
- Class Antiasthmatics
- Mechanism of Action Interleukin 5 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Asthma
Most Recent Events
- 28 Feb 2003 Suspended - Preclinical for Asthma in Australia (unspecified route)
- 28 Feb 2003 E 13R is available for licensing (http://www.bresagen.com.au)
- 11 Jul 2001 Preclinical development for Asthma in Australia (Unknown route)